Table 5.
Selected Trials of T-Cell Engaging Bi-Specific Antibodies in Multiple Myeloma (MM)
| Trial ID (References) | Treatment | Phase | Enrollment (N) | Trial Title |
|---|---|---|---|---|
| NCT02514239198 | AMG 420 | I | 43 | An open label, phase I, dose escalation study to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous doses of AMG 420 in RRMM patients |
| NCT03287908159,199 | AMG 701 alone vs (AMG 701 + Pom ± Dex) | I/II | 408 | A phase I/II open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of pavurutamab (AMG 701) monotherapy, or in combination with pomalidomide, with and without dexamethasone in subjects with RRMM (ParadigMM-1B) |
| NCT03761108162,200 | REGN5458 | I/II | 200 | Phase I/II FIH study of REGN5458 in patients with RRMM |
| NCT03145181167 | Tecl | I | 204 | A phase I, first-in-human, open-label, dose escalation study of teclistamab in subjects with RRMM |
| NCT04649359 | Elra | II | 150 | MAGNETISMM-3 an open-label, multicenter, non-randomized phase II study of elranatamab (PF-06863135) monotherapy in participants with MM who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody |
| NCT03486067 | CC-93269 | I | 175 | A phase I, open-label, dose finding study of CC-93269, a BCMA X CD3 T cell engaging antibody, in subjects with RRMM |
| NCT03933735180 | TNB-383B | I | 133 | A multicenter, phase I, open-label, dose-escalation and expansion study of TNB-383B, a bi-specific antibody targeting BCMA in subjects with RRMM |
| NCT04184050 | HPN217 | I/II | 70 | A phase I/II open-label, multicenter, dose escalation and dose expansion study of the safety, tolerability, and pharmacokinetics of HPN217 in patients with RRMM |
| NCT04434469 | RO7297089 | I | 80 | An open-label, multicenter, phase I trial evaluating the safety and pharmacokinetics of escalating doses of RO7297089 in patients with RRMM |
| NCT03399799196 | Talq | I | 245 | A phase I, first-in-human, open-label, dose escalation study of talquetamab in subjects with RRMM |
Abbreviations: Dex, dexamethasone; Elra, elranatamab; Len, lenalidomide; Pom, pomalidomide; Talq, talquetamab; Tecl, teclistamab.